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Abstract 
 
Many studies have found evidence of conditioning-induced nocebo hyperalgesia. However, 
these studies have exclusively involved continuous reinforcement schedules. Thus, it is 
currently unknown whether nocebo hyperalgesia can result following partial reinforcement. 
We tested this using electrodermal pain stimulation in healthy volunteers. Undergraduates 
(n=135) received nocebo treatment under the guise of a hyperalgesic. Participants were 
randomly allocated to continuous reinforcement (CRF), partial reinforcement (PRF), or 
control (no conditioning). Conditioning involved surreptitiously increasing pain stimulation 
on nocebo trials relative to control trials. During training, the CRF group always had the 
nocebo paired with the surreptitious pain increase, whereas the PRF group only experienced 
the increase on 62.5% of nocebo trials. In the test phase, pain stimulation was equivalent 
across nocebo and control trials. Partial reinforcement was sufficient to induce nocebo 
hyperalgesia, however, this was weaker than continuous reinforcement. Interestingly, nocebo 
hyperalgesia failed to extinguish irrespective of the training schedule. Additional assessment 
of expectancies indicated strong concordance between these and nocebo hyperalgesia. 
Overall, these findings suggest that once established, nocebo hyperalgesia may be difficult to 
disrupt. As such, partial reinforcement may be one method of reducing the intensity of 
nocebo hyperalgesia in the clinic, which may be particularly important given its persistence.  
Perspectives: This study provides novel evidence that partial reinforcement results in weaker 
nocebo hyperalgesia than continuous reinforcement and that nocebo hyperalgesia fails to 
extinguish, irrespective of the training schedule. As a result, partial reinforcement may serve 
as a method for reducing the intensity of nocebo hyperalgesia in the clinic.  
Keywords: Nocebo; pain; expectancy; conditioning; partial reinforcement 
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Nocebo hyperalgesia, partial reinforcement, and extinction 
Most research on placebo effects for pain has focused on placebo analgesia. However, 
increasing evidence indicates that placebo mechanisms can also amplify pain, referred to as 
nocebo hyperalgesia [5, 7, 14, 16, 28]. As with placebo analgesia, evidence of increased pain 
ratings during nocebo hyperalgesia is supported by neuroimaging studies demonstrating 
accompanying modulation of activity in brain regions known to be sensitive to pain [10, 20, 
29, 32]. However, while both placebo analgesia and nocebo hyperalgesia are considered to 
result from the same general learning mechanisms, i.e. instruction and conditioning, some 
asymmetries exist. For example, nocebo hyperalgesia is more readily induced via instruction 
than placebo analgesia is [16] and while endogenous opioids have been shown to underlie 
instruction-induced placebo analgesia [3, 8, 30, 31], instruction-induced nocebo hyperalgesia 
appears to be mediated by cholecystokinin [5, 6].  
Given the traditional focus on placebo analgesia, many of the characteristics of nocebo 
hyperalgesia are currently unknown. One important example is whether the conditioning 
schedule affects the magnitude of nocebo hyperalgesia. To date, studies investigating 
conditioned nocebo hyperalgesia have exclusively involved continuous reinforcement 
training schedules [10, 15, 16, 20, 28, 29], in which presentation of the nocebo was always 
followed by hyperalgesia during training. Thus, it is currently unknown whether nocebo 
hyperalgesia can result following more variable conditioning schedules in which the nocebo 
is only followed by hyperalgesia on some occasions during training, known as partial 
reinforcement [11, 17], which may be more ecologically valid. Further, only one study to date 
[16] has examined extinction of nocebo hyperalgesia, i.e. how long the effect lasts once 
established. Interestingly, that study found evidence suggesting that nocebo hyperalgesia fails 
to extinguish, which is contrary to what most learning models would predict.  
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Importantly, the type of training schedule may influence the rate of extinction. Numerous 
animal conditioning studies indicate a partial reinforcement extinction effect, whereby partial 
reinforcement produces conditioned responding that is more resistant to extinction than 
continuous reinforcement [22, 24, 25, 33]. Thus, nocebo hyperalgesia may be even more 
resistant to extinction than it currently appears when it is established under partial 
reinforcement.  
The current study addressed these gaps in knowledge by comparing the magnitude and 
rate of extinction of nocebo hyperalgesia following continuous and partial reinforcement 
schedules using experimentally-induced pain. We recently conducted the only study to date 
comparing continuous and partial reinforcement on placebo analgesia and found that partial 
reinforcement produced weaker placebo analgesia than continuous reinforcement, but that the 
placebo analgesia established under partial reinforcement was more resistant to extinction [4]. 
If the training schedule affects nocebo hyperalgesia in a similar way, then one would expect 
weaker initial nocebo hyperalgesia following partial reinforcement that is more resistant to 
extinction compared with continuous reinforcement. However, given the asymmetries 
mentioned above, it seemed quite plausible from the outset that partial reinforcement may 
affect the development of nocebo hyperalgesia differently to its effects on placebo analgesia. 
Understanding the characteristics of nocebo hyperalgesia is important for discovering ways 
of reducing its contribution to pain in the clinic. To our knowledge, this is the first test of 
whether nocebo hyperalgesia can result following partial reinforcement.     
 
METHODS 
Participants 
One-hundred and thirty-five (54% female; mean age=20.3, SD=4.0) undergraduate 
students from the University of Sydney participated. One-hundred and fifteen were first year 
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Psychology students who participated in return for course credit. For these participants, the 
study was advertised on an internal website where over 2,000 first year psychology students 
can select to participate in various studies. The remaining 20 participants were undergraduate 
students recruited from the general university population via a volunteer website and were 
reimbursed $15 for their participation. To be included, participants had to be fluent in 
English, not have any current or previous heart problems, not currently be experiencing pain, 
and not have participated in any other placebo-related studies within the School of 
Psychology. All participants provided informed consent and the study procedures were 
approved by the University of Sydney’s Human Research Ethics Committee.  
 
Design 
The design followed our previous study on partial reinforcement and extinction of 
placebo analgesia [4]. The key exception was that participants were told that they were taking 
part in a study testing whether Transcutaneous Electrical Nerve Stimulation (TENS) could 
increase pain sensitivity, with participants in the experimental groups receiving conditioning 
with a surreptitious increase in pain. Table 1 shows the full study design. The TENS was 
actually a dummy device with its supposed ‘activation’ signalled by tactile vibration and a 
beeping sound. Participants were randomly allocated to one of three groups. The continuous 
reinforcement group (CRF) received training in which every time the TENS was activated 
(nocebo trials), the pain simulation was surreptitiously increased relative to no TENS trials 
(control trials). The partial reinforcement group (PRF) received training in which on only 
62.5% of nocebo trials the pain stimulation was surreptitiously increased relative to control 
trials, but on the remaining 37.5% of nocebo trials the pain stimulation remained the same as 
control trials. A 62.5% PRF schedule was chosen to approximate a ratio of reinforcement to 
non-reinforcement of 2:1 to simulate a treatment setting in which the treatment regularly, but 
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not always leads to hyperalgesia. A control group was told that they were acting as controls 
and would not receive any TENS. Instead, they were led to believe that the dummy device 
measured skin conductance and that it would only be activated on half the trials to ensure that 
it did not interfere with any of the other equipment. In this group, activation of the device and 
level of pain stimulation were non-contingent such that the pain was surreptitiously increased 
on half of the trials with the device active and half of the trials with the device inactive. This 
was done in blocked fashion as per Au Yeung et al [4] to avoid any potential superstitious 
conditioning. For all groups, the training phase consisted of 32 trials in total: 16 trials with 
the device active and 16 control trials. This meant that the CRF group experienced 16 
pairings of the nocebo with increased pain stimulation whereas the PRF group experienced 
10 pairings of the nocebo with increased pain stimulation and 6 nocebo trials with not 
increase in level of pain stimulation.  
 
[TABLE 1 HERE] 
 
The test phase occurred immediately after the conditioning phase, with no break or signal 
that a new phase had begun. In this phase, all groups underwent a further 16 trials with the 
device active and 16 control trials with the device inactive, all with the pain stimulation kept 
at the intensity administered for control trials during training regardless of whether the device 
was active or not. This provided the test of nocebo hyperalgesia and whether or not it 
extinguished after the reinforcement was withdrawn.  The dependent variable was pain report 
following each painful stimulus. In a novel addition to the current study, we also assessed 
participants’ expectancies for pain prior to each individual painful stimulus, which allowed us 
to test how the conditioning manipulations affected expectancy as well as the relationship 
between expectancy and nocebo hyperalgesia.   
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Materials 
Verbal instructions. All participants were given an information sheet on arrival that 
described TENS only briefly as involving passing an electrical current through the skin, with 
no suggestion of how this might affect their pain. The two conditioning groups received more 
substantial information on TENS as follows. Prior to the dummy device being attached, they 
received a one page handout including sections “What is TENS used for?”, “How does TENS 
work?”, and “What’s so good about TENS?” The handout suggested that TENS was effective 
for enhancing pain by “enhancing the conductivity of the pain signal being sent to the brain”. 
The conditioning groups were also given oral instructions that supported this as the nocebo 
device was being attached to their arm. These instructions were: 
“This is the TENS electrode [researcher shows participant the nocebo device]. TENS 
stands for transcutaneous electrical nerve stimulation. TENS can increase pain by 
amplifying the pain signals as they travel up your arm and into your brain [researcher 
follows the path from the electrode placement up the participant’s arm]. The TENS itself 
is not painful, but you will feel a small sensation when it’s turned on. I’ll give you an 
example of what it feels like now.” 
 The control group were given no additional information about TENS other than the brief 
mention in the initial information sheet. They did not receive the TENS handout. They only 
received oral instructions suggesting that a device measuring skin conductance was being 
attached to their arm. The instructions were: 
“You have been allocated to the control group, which means that you will not receive 
TENS. But, your skin conductance will still be measured. This is the electrode that 
measures skin conductance [researcher shows participant the device]. Skin conductance 
is a measure of autonomic arousal. You will feel a slight sensation when the skin 
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conductance is being recorded, but it won’t be painful. Because the skin conductance 
electrode can interfere with other equipment, we will only turn it on half the time. I’ll 
give you an example of what it feels like now.” 
 
Nocebo device. No TENS was actually delivered to participants at any stage of the 
experiment. TENS was simply used as a cover story to explore nocebo hyperalgesia. The 
device was a stimulus isolator (Model FE180, ADInstruments) that generated tactile 
stimulation via direct currents sent to electrodes attached on the dorsal forearm on the 
participant’s non-dominant hand. A full description can be found in [4]. 
 
Pain stimuli.  Pain was induced via electro-cutaneous stimulation similar to that used in 
other studies on placebo analgesia [4, 13, 15]. Electrically-induced pain was chosen because 
the intensity of the stimulation can easily be manipulated surreptitiously to achieve 
conditioning and, unlike some other devices, e.g. CO2 laser, it allows repeated stimulation at 
the same site without risk of tissue damage. Each stimulus consisted of an electrical shock 
delivered to the dorsum of the participant’s non-dominant hand via two silver chloride 
electrodes, each approximately 1cm apart.  Stimuli were generated by a pain stimulator 
(Model SHK1, Contact Precision Instruments). The stimuli were square pulses with duration 
of 0.5 sec and frequency of 100 Hz.  
The intensity of the pain stimuli was calibrated for each participant individually prior to 
testing. This was done by initially delivering stimuli at a very low and usually imperceptible 
level and then increasing the intensity of the stimuli in steps until participants reached a level 
that they felt was “definitely painful, but tolerable”. To ensure this was at least somewhat 
painful and to avoid potential floor effects, when this level was reached, the participant was 
asked to verbally report their pain out of 10, with 0 being no pain and 10 being very painful. 
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If their reported pain was less than 6 out of 10, then they were asked whether they felt 
comfortable trying a higher intensity, such that participants’ pain ratings at the end of 
calibration were at least 6 out of ten on a verbally reported scale. The level of intensity 
reached at the end of calibration was labelled as the 100% intensity for that particular 
participant. Intensity of each stimulus during the experiment was determined on the 
individual’s 100% intensity level, their experimental condition, and the particular trial. 
 
Pain ratings. Participants were asked to rate their pain following each painful stimulus on 
a 100 point computerised visual analogue scale (VAS). Three anchors were used, with 0 (No 
pain) and 100 (Very painful) on the left and right extremes respectively, and 50 (Moderately 
painful) in the middle. 
 
Expectancy ratings. Participants were also asked to rate their expectancy before each 
painful stimulus. This was done on response meter (model MLT1601/ST, ADInstruments, 
Sydney, NSW) in which the participant could move a slider with their dominant hand to rate 
how painful they expected the next shock to be on a 100-point VAS with the anchors labelled 
as 0 (No pain), 50 (Moderately painful), and 100 (Very painful).  
 
Trial structure and conditioning manipulation. Each trial consisted of a single pain 
stimulus followed by a pain rating. Within a given trial, each pain stimulus was signalled by a 
10 second countdown culminating in an "X" appearing on the computer screen, 0.5 seconds 
after which the painful stimulus was delivered. A prompt appeared on the screen reminding 
participants to rate their expectancy for 7 secs during the countdown. After each stimulus, 
participants rated the intensity of the pain on the computerised VAS. In between each trial, 
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participants had a rest of 10-15 seconds. On nocebo trials, the device was activated for 8sec 
during the countdown. On control trials, the device remained inactive.  
The conditioning phase included 16 nocebo and 16 control trials. The CRF group 
received a surreptitious increase in painful stimulation on all 16 nocebo trials. This was 
achieved by increasing the pain intensity to 100% on nocebo trials as opposed to 60% on 
control trials, a similar sized increase to those previously used in conditioned nocebo 
hyperalgesia studies [16]. The PRF group received the same surreptitious increase in painful 
stimulation, but only on 62.5% of nocebo trials; that is, pain intensity was increased on 10 out 
of the 16 nocebo trials, as shown in Table 1. The nocebo trials were intermixed with control 
trials in quasi-randomised order within participants, such that there were no more than two 
nocebo or control trials in a row. This trial order was employed to ensure that the different 
trials were distributed across the test session both within and across participants. For the 
control group, the conditioning phase also involved 16 trials with the device active and 16 
with it inactive. Half of each of these trials were at 100% pain intensity with the other half at 
60% pain intensity. These trials were presented in four blocks of 8 trials (4 trials with the 
device active and 4 with the device inactive) with two blocks being at 100% intensity and 
four at 60% intensity. This variation ensured that as with the experimental groups, the control 
group also had some experience of different levels of pain and using the pain scale as 
opposed to if they only ever received 100% painful stimulation [4]. The blocked design was 
intended to prevent potential superstitious conditioning, even though the two events were 
non-contingent. 
The test/extinction phase was identical for all groups. It consisted of 32 trials (16 with the 
device active and 16 with it inactive) in which the intensity of painful stimuli was always set 
at 60%. This provided the test of whether the CRF and PRF groups would experience greater 
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pain on nocebo trials relative to control trials despite the actual level of stimulation being 
identical across the two.  
   
Exit questionnaire. An exit questionnaire tested whether participants guessed the true 
nature of the study, as well as their knowledge of the placebo-shock reduction contingency 
across groups. The first question asked: "What do you think the study was about?" with an 
open response. The second and third questions assessed contingency knowledge for the first 
and second half of the experiment, respectively. The questions read "In the first [or second] 
half of the experiment, did you notice any increase in pain when TENS was turned on 
compared with when it was not turned on?".  
 
Procedure 
 Participants attended a single one-hour session and were tested individually in an 
isolated testing booth. Upon arrival, they were given an information sheet that described the 
study as a test of the acute effect of TENS on psychophysiological responses to pain. The two 
conditioning groups were then told that they had been allocated to receive TENS and were 
given the handout on TENS. The control group was told that they had been allocated to 
receive no treatment and simply rested for two minutes. The nocebo device was then 
introduced and attached to the participant, during which each group was given the relevant 
oral instructions.  
The experimenter then explained the trial structure to the participant, left the room, 
and then initiated the computerised programme that controlled the delivery of the pain 
stimuli, activation of the ‘TENS’ device, and pain ratings. The conditioning phase was 
initiated and was followed immediately by the test/extinction phase without any notification 
to the participant. At the end of the test/extinction phase, participants completed the exit 
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questionnaire assessing their beliefs about the study. A debrief statement was sent to all 
participants via email at the completion of the study.  
 
Data handling and analysis 
 Thirteen participants were excluded based on a priori criteria: six were not proficient in 
English, three had already completed a study on placebo effects in our laboratory, and four 
rated pain as less than 30 out of 100 on trials with 100% pain intensity during the training 
phase. A further three participants were excluded ad hoc for failing to follow instructions. 
This left 119 participants with evaluable data.  
ANOVA and Chi-square tests of independence tested for baseline differences in age and 
gender. For the main analysis on the pain data, conditioning and test phases were analysed 
separately. In each phase, the groups were compared by calculating difference scores between 
pain with and without the ‘TENS’ device activated (difference = pain with TENS – pain 
without TENS; positive scores indicated nocebo hyperalgesia) that were analysed via mixed 
ANCOVAs with group and trial as factors, controlling for age and gender. Age and gender 
were included as covariates as both have been found to influence pain perception in general 
[21, 38] as well as the placebo effect specifically [37]. However, the pattern of results were 
identical without these covariates included in the model. The critical test of the magnitude of 
the nocebo hyperalgesia produced by each conditioning schedule was the difference in pain 
ratings on the first nocebo trial and control trial in the test/extinction phase, i.e. Trial 17. We 
expected that the strongest nocebo hyperalgesic effect would occur immediately after the 
conditioning phase. This is because the first test trial occurs before any extinction has taken 
place. To explore changes over time and compare rates of extinction across the groups, we 
tested linear trends whenever trial was included as factor. To isolate the effects of the 
different conditioning schedules we conducted planned pairwise comparisons between each 
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group. These inter-group comparisons were repeated for the expectancy data, to test how 
training influenced the acquisition of expectancies and their time course during the test phase. 
Multiple linear regression was then used to test the extent to which expectancy predicted 
nocebo hyperalgesia in each group, controlling for age and gender.    
All analyses were conducted in IBM SPSS Statistics 20.0, covariates were mean centred 
to reduce multicollinearity and the assumptions of covariate-treatment independence and 
homogeneity of regressions slopes were met, Greenhouse-Geisser corrections were made 
whenever the sphericity assumption was not met (in which case adjusted degrees of freedom 
are reported), and results were considered statistically significant when p<.05.    
 
RESULTS 
There were no statistically significant differences in age or gender across the three 
groups, F2,116=1.63, p=.20 and χ2 (df=2, N=119)=3.09, p=.21, respectively.  
 
Pain  
Training Phase: Pain ratings during training are shown in Figure 1. There was no 
statistically significant difference in pain ratings averaged across the 60% trials when the 
nocebo device was inactive during training (F2,114=0.91, p=.41, 2p=.02), suggesting no 
differences in overall pain sensitivity between groups. The conditioning manipulation was 
effective in producing increased pain in both the CRF and PRF group on relevant nocebo 
trials during training. In the CRF group, pain was rated as 36.6 (SD=13.5) points higher on 
nocebo trials with the 100% pain stimulation relative to the control trials (always 60% pain 
stimulation: F1,34=247.0, p<.001, 2p=.88). In the PRF group, pain was rated 27.3 (SD=10.0) 
points higher on nocebo trials with 100% pain stimulation than on control trials (F1,37=265.0, 
p<.001, 2p=.88). There was also evidence of some nocebo hyperalgesia in the PRF group 
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during training, whereby pain was rated as 11.3 (SD=11.1) points higher on nocebo trials 
with 60% pain stimulation than on control trials with 60% stimulation (F1,37=33.6, p<.001, 
2p=.48). The difference in the magnitude of the pain increase on reinforced nocebo trials 
during training was significantly greater for the CRF group than the PRF group (F1,77=11.9, 
p=.001, 2p=.14). In the control group, there was no difference in pain ratings when the device 
was active or inactive at 100% pain stimulation (F1,39=1.74, p=.20, 2p=.04). However, at 60% 
pain stimulation, pain ratings were statistically significantly higher with the device active 
relative to when it was inactive (F1,39=6.89, p=.01, 2p=.15), but this was only by 1.49 
(SD=4.0) points out of 100. Overall then, the training phase indicated that the conditioning 
manipulation was effective with only a very slight, if any unconditioned effect of having the 
device active on pain ratings.  
 
[FIGURE 1 HERE] 
 
Test Phase: Pain ratings during the test phase - where all pain stimulation was set to 60% 
irrespective of whether or not the device was active - are shown in Figure 1. Differences in 
these pain ratings on nocebo and control trials were compared between groups on the first test 
trial (where conditioning should be strongest) as well as over the entire test phase. A 
summary of the results for the test phase is presented in Table 2. On the first test trial, there 
was a statistically significant main effect of group (F2,114=4.37, p=.01, 2p=.07). Pairwise 
comparisons revealed statistically significant nocebo hyperalgesia in the CRF group, with the 
hyperalgesia induced by the nocebo being 8.9 points greater than control (F1,114=8.75, p=.004, 
2p=.07). There was no statistically significant nocebo hyperalgesia in the PRF group relative 
to control on the initial test trial (F1,114=1.83, p=.18, 2p=.02), nor was nocebo hyperalgesia in 
the CRF significantly greater than the PRF group (F1,114=2.44, p=.12, 2p=.02).  
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 The two-way treatment by trial analysis over the entire test phase also revealed a 
statistically significant main effect of treatment (F2,114=10.1, p<.001, 2p=.15). Pairwise 
comparisons indicated a statistically significant nocebo hyperalgesic effect of 8.9 points in 
the CRF group versus control when averaged across all test trials (F1,114=20.2, 
p<.001, 2p=.15). There was also a statistically significant nocebo hyperalgesic effect of 4.0 
points in the PRF group relative to control (F1,114=4.26, p=.04, 2p=.04). The strength of the 
nocebo hyperalgesia was significantly greater in the CRF group relative to the PRF group 
(mean diff=4.76, F1,114=5.57, p=.02, 2p=.05). There was, however, no main effect of trial nor 
a significant group by trial interaction (F10.4,1710=1.41, p=.13, 2p=.01 and F20.9,1710=0.93, 
p=.55, 2p=.02, respectively), suggesting that once established, the nocebo hyperalgesic 
effects did not extinguish. This was confirmed in the pairwise comparisons, with no 
significant interaction between any of these and the linear trends across trials (all F<1).  
 
[TABLE 2 HERE] 
Expectancy  
 Training Phase: Expectancy ratings for each of the groups are shown in Figure 1. As 
with the pain ratings, differences in expectancy ratings on nocebo versus control trials were 
calculated (labelled ‘nocebo expectancy’) and compared across groups. In the training phase, 
there were significant main effects of trial and treatment on nocebo expectancy 
(F10.5,1710=7.82, p<.001, 2p=.06 and F2,114=15.2, p<.001, 2p=.21, respectively) as well as a 
significant time by treatment interaction (F21.0,1710=2.70, p<.001, 2p=.05).  Pairwise 
comparisons between groups indicated that the CRF group expected an average of 16.7 points 
more pain than the control group on nocebo relative to control trials during training 
(F1,114=30.0, p<.001, 2p=.21) . Similarly, the PRF group expected an average of 9.3 points 
more pain than control group on these trials (F1,114=9.43, p=.002, 2p=.08). Further, the CRF 
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group expected significantly more pain on nocebo relative to control trials than the PRF 
group during training by an average of 7.3 points (F1,114=5.49, p=.02, 2p=.05). Significant 
linear interactions across trials between CRF and control as well as between PRF and control 
(F1,114=19.9, p<.001, 2p=.15 and F1,114=11.4, p=.001, 2p=.09, respectively) indicated that the 
greater nocebo expectancy in the experimental groups relative to control increased over the 
course of training, consistent with typical learning acquisition curves. There was no such 
significant interaction between the CRF and PRF groups (F1,114=1.16, p=.28, 2p=.01) 
suggesting that despite the higher overall nocebo expectancy for pain in the CRF group, the 
rate this increased over training was similar in the CRF and PRF groups.  
Test Phase:  A summary of the results for the test phase is presented in Table 2. On the 
first test trial of the test phase, there was a significant main effect of treatment on nocebo 
expectancy (F2,114=15.2, p<.001, 2p=.21). Pairwise comparisons revealed that the CRF group 
expected 26.4 points more pain on nocebo trials relative to control trials than the control 
group did (F1,114=25.1, p<.001, 2p=.18). Similarly, the PRF group expected 23.0 points more 
pain than the control group did on nocebo relative to control trials (F1,114=19.9, p<.001, 
2p=.14). The slightly numerically higher nocebo expectancy in the CRF group on the first test 
trial compared with the PRF group was not statistically significant (F1,114=0.40, p=.53, 
2p<.01).   
The two-way treatment by trial analysis over the entire test phase also revealed a 
statistically significant main effect of treatment on nocebo expectancy (F2,114=15.6, p<.001, 
2p=.22). Pairwise comparisons indicated statistically significantly higher nocebo expectancy 
of 16.2 points in the CRF group versus control when averaged across all test trials 
(F1,114=27.6, p<.001, 2p=.20). Nocebo expectancy was also statistically significantly higher in 
the PRF group by 12.7 points than the control group (F1,114=17.2, p<.001, 2p=.13). As with 
the first trial, nocebo expectancy averaged across the entire test phase was numerically higher 
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in the CRF group than the PRF, but this was not statistically significant (F1,114=1.21, p=.27, 
2p=.01). There was also a significant main effect of trial (F10.3,1710=1.99, p=.03, 2p=.02) and a 
significant treatment by trial interaction (F20.6,1710=1.70, p=.03, 2p=.03). An overall negative 
linear trend across trials suggested that nocebo expectancy decreased over the course of the 
test phase (F1,114=7.73, p=.006, 2p=.06). There was a significant interaction in this linear 
trend between the CRF group and the control group (F1,114=6.56, p=.01, 2p=.05), suggesting a 
sharper decline in nocebo expectancy in the CRF group. There was no significant interaction 
in linear trends in expectancy between the PRF and control group, nor the CRF and PRF 
groups (F1,114=1.21, p=.27, 2p=.01 and F1,114=2.02, p=.16, 2p=.02).  This suggested that there 
was some extinction of nocebo expectancy in the CRF group relative to control, but not for 
PRF relative to control, nor between CRF and PRF.  
 
[FIGURE 2 HERE] 
 
Expectancy and Nocebo Hyperalgesia 
 Figure 2 shows scatterplots of nocebo expectancy and nocebo hyperalgesia averaged 
across the test phase for each group. Multiple linear regressions controlling for age and 
gender indicated that expectancy was a significant predictor of hyperalgesia within each 
group. For the CRF group, a 10-point (out of 100) increase in expectancy significantly 
predicted a 3.5 point increase in pain (b=.350, t1,33=3.94, p<.001, unique R
2=.307). Despite 
this already being a relatively large effect size, it was apparent that there was one clear outlier 
within the CRF group. As can be seen in Figure 2A, this participant had mean nocebo 
expectancy of -39.2 (i.e. expected 39.2 points less pain when the nocebo was activated), 
which was 3.2 standard deviations below the mean nocebo expectancy of 17.3 (SD=17.8) in 
the CRF group. Removing this participant from this analysis, the unique proportion of 
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variability accounted for by expectancy in the CRF increased substantially, with a 10-point 
increase in expectancy now significantly predicting an increase of 5.2 points in pain (b=.516, 
t1,32=5.91, p<.001, unique R
2=.507).  
In the PRF group, a 10-point increase in expectancy significantly predicted an increase of 
4.7 points in pain (b=.474, t1,36=6.77, p<.001, unique R
2=.547). In the control group, a 10-
point increase in expectancy significantly predicted an increase of 5.2 points in pain (b=.517, 
t1,38=4.84, p<.001, unique R
2=.370). This meant that after controlling for age and gender, 
nocebo expectancy uniquely accounted for 50.7% of the variance in nocebo hyperaglesia in 
the CRF group, 54.7% in the PRF group, and 37.0% in the control group. These are 
substantial effect sizes, especially in the experimental groups, and demonstrate strong 
concordance between expectancy and nocebo hyperalgesia.   
 
Exit questionnaire 
 The majority of participants appeared to find the cover story credible. Only 26 (22%) 
made reference to any placebo-related effects. Specifically, 23 (19%) mentioned the effect of 
expectancy, anticipation, or thoughts on pain, two (<2%) mentioned conditioning, and only 
one (<1%) specifically mentioned the placebo effect. The rates of these responses were 
highest in the control group (33%), followed by the PRF group (22%), and the CRF group 
(8%).    
 
DISCUSSION 
 The current study tested the effect of different reinforcement schedules on nocebo 
hyperalgesia. Four key findings emerged. First, nocebo hyperalgesia can result following 
partial reinforcement. Second, nocebo hyperalgesia produced by partial reinforcement is 
weaker than that produced by continuous reinforcement. Third, nocebo hyperalgesia is 
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resistant to extinction independently of the training schedule. Fourth, there is strong 
concordance between expectancy and nocebo hyperalgesia. These findings have a number of 
important theoretical and practical implications.  
 First, this study provides novel evidence that nocebo hyperalgesia can result following 
partial reinforcement. This extends previous evidence of nocebo hyperalgesia following 
continuous reinforcement [10, 15, 16, 20, 28, 29], by demonstrating that nocebo hyperalgesia 
can result even when the contingency between the the nocebo and the nociceptive stimulus is 
more variable - as may often be the case outside of the laboratory. Thus, the current study 
increases the ecological validity of laboratory research on nocebo hyperalgesia. It is, 
however, important to emphasise that the magnitude of the nocebo hyperalgesia produced 
following partial reinforcement was weaker than that produced following continuous 
reinforcement. Using Cohen’s [12] rules of thumb, the nocebo hyperalgesia induced by 
continuous reinforcement had a large effects size (2p=.15) whereas for partial reinforcement 
it was moderate-to-weak (2p=.04).  Weaker nocebo hyperalagesia following partial 
reinforcement  is consistent with animal studies that have found evidence of weaker 
conditioned responding following partial reinforcement compared with continuous 
reinforcement [1, 2, 19].  
 Perhaps most interestingly, the nocebo hyperalgesia we induced failed to extinguish 
independently of the training schedule. That is, the higher pain on nocebo trials compared 
with control trials remained constant during the entire test period following training under 
both partial and continuous reinforcement. This points towards another asymmetry between 
nocebo hyperalgesia and placebo analgesia in that we recently found that placebo analgesia 
produced under continuous reinforcement does extinguish [4]. While resistance to extinction 
of nocebo hyperalgesia following partial reinforcement is consistent with partial 
reinforcement extinction effects observed in other areas [33], the failure of the nocebo 
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hyperalgesia established under continuous reinforcement to extinguish could be considered 
more surprising. This is because conditioned responding following continuous reinforcement 
typically extinguishs in humans and animals both in general and in fear conditioning studies 
specifically, which also involve delivery of electrodermal shocks [23].  
 However, there is already some empirical evidence suggesting that nocebo hyperalgesia 
established under continuous reinforcement fails to extinguish. Specifically, Colloca et al. 
[16] found that nocebo hyperalgesia was maintained across six extinction trials following 
continuous reinforcement. Current models propose that nocebo hyperalgesia is at least 
partially mediated by increased anxiety, one of which’s effects is activation of 
cholecystokinin (CCK) receptors that potentiate pain [18]. Coupled with evidence that people 
with anxiety disorders, such as PTSD, exhibit impaired extinction of conditioned fear 
responses [36], it may be the case that nocebo stimuli induce heightened anxiety that impairs 
extinction and results in persistent nocebo hyperalgesia. Given that both the current and 
Colloca et al.’s studies involved healthy participants and not ones with anxiety disorders, this 
may seem at odds with fear conditioning studies on healthy participants, which do show 
extinction [23]. However, in fear conditioning studies the extinction phase involves the entire 
removal of the aversive stimulus (i.e. CS→no shock), whereas in nocebo hyperalgesia studies 
it involves a reduction of the intensity of the painful stimulation, not its entire removal (i.e. 
nocebo → reduced shock). Thus, it may be that experiencing painful, albeit weaker stimuli 
throughout extinction phases in nocebo hyperalgesia studies induces sustained heightened 
anxiety that impairs extinction. Importantly, the current study extends Colloca et al.’s by 
demonstrating that nocebo hyperalgesia following continuous reinforcement fails to 
extinguish even after substantially longer extinction testing involving a total of 16 test trials, 
suggesting that its persistence is more than temporary.   
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 Another novel aspect of the current study was our trial-by-trial expectancy.  These 
generally indicated strong concordance nocebo hyperalgesia. Expectancy accounted for 
between 48-54% of the variance in nocebo hypalgesia in the CRF and PRF groups - a very 
large effect and one that is consistent with prominent models of the placebo effect that view 
expectancy as a key mechanism [9, 26, 27, 35]. However, while there was no evidence of 
extinction of nocebo hyperalgesia in either experimental group, expected hyperalgesia did 
decrease over the course of the test phase in the CRF group relative to the control group. This 
suggests some level of discordance between expectancy and nocebo hyperalgesia at least in 
terms of extinction. However, because the two involve fairly different types of ratings, that is 
an appraisal of pain versus an appraisal of a belief, any apparent discordance could be due to 
differences in the sensitivity of each type of rating to detect changes.  
The effect of training schedule on nocebo hyperalgesia and its failure to extinguish have 
some important clinical implications. The current result suggests that interspersing delivery 
of an active treatment that produces hyperalgesia with a placebo (i.e. partial reinforcement) 
could reduce the strength of any nocebo hyperalgesia developed during treatment and thereby 
reduce the overall pain experienced by the patient. The reduction in nocebo hyperalgesia 
following partial reinforcement relative to continuous reinforcement approached a moderate 
effect size (2p=.05) [12]. Given that the effect size for continuous reinforcement was large 
(2p=.15), this suggests that using partial reinforcement could lead to substantial benefits to 
patients in the clinic. Further, reducing the magnitude of nocebo hyperalgesia may be 
particularly important given its apparent persistence following both continuous and partial 
reinforcement. If the current failure of nocebo hyperalgesia to extinguish generalises to 
clinical settings, then once established, nocebo hyperalgesia may be difficult to disrupt. If so, 
then clinicians should make every effort to prevent the development of nocebo hyperalgesia 
in the first place, otherwise it may persevere indefinitely. Furthermore, nocebo effects that 
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failed to extinguish in perpetuity could call into question the ethicality of conducting nocebo 
research.    
 Some potential limitations to the current study are worth considering. First, although we 
did not observe any extinction of nocebo hyperalgesia, it is possible that extinction may be 
observed if we extended the test phase. Importantly, however, the test phase used here 
involved 16 test trials, which is almost three times longer than in Colloca et al. [16] and the 
same amount that we observed clear extinction of placebo analgesia [4]. Thus, any potential 
eventual extinction of nocebo hyperalgesia would likely require substantially longer testing 
and may not necessarily eventuate under those circumstances. Second and related, extinction 
was tested in a single session. As such, it would be interesting to test whether the current 
findings generalise to a clinical setting in which both training and testing occur over multiple 
days, rather than a single session. At least one study suggests that nocebo hyperalgesia 
established via instruction alone can be maintained for up to 90 days [34], but we are 
unaware of any studies testing the effects of conditioned nocebo hyperalgesia over multiple 
days. Given that there was some evidence of a decrease in expectancy over the test phase in 
the CRF group, but not the PRF group, it could be the case that if testing over multiple days 
does lead to extinction of nocebo hyperalgesia, then this nocebo hyperalgesia may be more 
resistant to extinction under partial reinforcement. That is, while there was no partial 
reinforcement extinction effect observed here in the single session employed here, such an 
effect may exist with chronic pain and treatment outcomes. Third, there was an asymmetry 
between the CRF and PRF groups in terms of the total number of reinforced nocebo trials 
they experienced during training. This was an intentional decision in order to match the total 
length of training across the two groups. Nonetheless, it would be interesting for future 
studies to compare the effects of different reinforcement schedules on nocebo hyperalgesia 
matched on the number of reinforced trials compared with matched on training length.. 
 Page 24 of 32 
 
Finally, a major strength of the current study was the inclusion of trial-by-trial expectancy 
assessment. However, it is possible that assessing expectancy may have provided participants 
clues about the true nature of the study, with a higher number of participants reporting that 
the experiment was concerned with expectancy and pain in the exit questionnaire than in our 
previous study on placebo analgesia that did not assess expectancy [4]. This is a potentially 
difficult problem to overcome and is in fact the reason that we have previously avoided 
asking participants to report their expectancies. It would be interesting for future studies to 
experimentally test the extent to which assessing expectancy does influence placebo 
responding and/or participants’ beliefs about the purpose of a study.  
 Overall then, the current study provides novel evidence that nocebo hyperalgesia can 
result following partial reinforcement, that this nocebo hyperalgesia is weaker than that 
produced by continuous reinforcement, and that both are resistant to extinction. The weaker 
nocebo hyperalgesia following partial reinforcement suggests that it could be used in the 
clinic to reduce the development of nocebo hyperalgesia during active treatments, which may 
be particularly important given nocebo hyperalgesia’s apparent persistence once established.  
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Tables 
 
Table 1. Summary of study design. In the CRF and PRF groups the participants were led to believe the nocebo 
device was a TENS machine that would increase their pain. In the control group, the participants were told that 
the same device was a method of measuring skin conductance, with no mention of any potential effects on pain. 
The device was active on half the trials and inactive on the other half.  The active trials in the CRF and PRF 
groups constituted the  nocebo trials. Inactive trials are labelled control trials.  
 
Group Instruction Conditioning Test/Extinction 
CRF 
(n=37) 
 
 
Told receiving TENS  
to increase pain  
16 nocebo → 100% 
16 control → 60% 
16 nocebo → 100% 
16 control → 100% 
PRF 
(n=40) 
Told receiving TENS 
to increase pain 
10 nocebo → 100% 
6  nocebo → 60% 
16 control → 60% 
 
16 nocebo → 100% 
16 control → 100% 
Control 
(n=42) 
Told no treatment 
controls  
8 active + 8 control → 100% 
8 active + 8 control → 60% 
16 nocebo → 100% 
16 control → 100% 
 
 
  
 Page 30 of 32 
 
Table 2. Summary of ANCOVA models and relevant pairwise comparisons for pain and 
expectancy during the test phase. Omn. refers to the omnibus test for that component of the 
model.  
 
  
  
 Group Trial Group by Trial 
 
Omn
. 
Pairwise 
Omn
. 
Linea
r 
Trend 
 
Pairwise x Linear 
Trend 
 CRF 
vs 
CON 
PRF 
vs 
CON 
CRF 
vs 
PRF 
Omn
. 
CRF 
vs 
CON 
PRF 
vs 
CON 
CRF 
vs 
PRF 
Pain 
Frist test trial 
F 
p 
4.37 
.01 
8.75 
.004 
1.83 
.18 
2.44 
.12 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
All test trials 
F 
p 
10.1 
<.00
1 
20.2 
<.00
1 
4.26 
.04 
5.57 
.02 
1.41 
.13 
1.48 
.23 
.93 
.55 
.39 
.54 
.35 
.55 
.01 
.98 
Expectancy 
Frist test trial 
F 
p 
15.2 
<.00
1 
25.1 
<.00
1 
19.9 
<.00
1 
.40 
.53 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
All test trials 
F 
p 
15.6 
<.00
1 
27.6 
<.00
1 
17.2 
<.00
1 
1.21 
.27 
1.99 
.03 
7.73 
.006 
1.70 
.03 
6.56 
.01 
1.21 
.27 
2.02 
.16 
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Figures 
 
 
 
Figure 1. Covariate (age, gender) adjusted mean (±SE of mean difference) pain (A, C, E) and 
expectancy ratings (B, D, F) with the device active versus inactive for the continuous 
reinforcement group. 
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Figure 2. Covariate (age, gender) adjusted scatterplot of nocebo expectancy and nocebo 
hyperalgesia averaged across the test phase separately for each group. Lines reflect the slope 
of expectancy predicting hyperalgesia in the multiple linear regression controlling for age and 
gender. In the CRF group (A), there was one clear outlier who had averaged expectancy more 
than three standard deviations below the mean for that group (hollow circle), with the lighter 
dashed line showing the regression slope with that participant excluded. 
 
